期刊论文详细信息
Current Oncology
Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
Ritesh R. Kotecha1  Rupesh Kotecha2  Minesh P. Mehta2  Raees Tonse2  Haley Appel2  Yazmin Odia3  Guilherme Rabinowits3 
[1] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA;Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA;
关键词: meningioma;    cabozantinib;    VEGF;    targeted therapy;   
DOI  :  10.3390/curroncol28020145
来源: DOAJ
【 摘 要 】

Recurrent meningiomas remain a substantial treatment challenge given the lack of effective therapeutic options aside from surgery and radiation therapy, which yield limited results in the retreatment situation. Systemic therapies have little effect, and responses are rare; the search for effective systemic therapeutics remains elusive. In this case report, we provide data regarding significant responses in two radiographically diagnosed intracranial meningiomas in a patient with concurrent thyroid carcinoma treated with cabozantinib, an oral multitarget tyrosine kinase inhibitor with potent activity against MET and VEGF receptor 2. Given the clinical experience supporting the role of VEGF agents as experimental therapeutics in meningioma and the current understanding of the biological pathways underlying meningioma growth, this may represent a new oral therapeutic alternative, warranting prospective evaluation.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次